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ABSTRAK 
Kewujudan ubat-ubatan tiruan yang membawa implikasi negatif kepada masyarakat 
umum, pihak kerajaan dan syarikat-syarikat farmaseutikal menggesa campurtangan 
undang-undang bagi menangani masalah tersebut. Justeru, objektif kajian ini ialah 
untuk mengenalpasti bagaimana peruntukan lessen wajib menurut peruntukan undang-
undang yang berkaitan boleh digunapakai untuk menangani masalah percambahan 
penghasilan ubat-ubatan tiruan di Nigeria. Bagi menjawab persoalan tersebut, kajian 
ini menggunapakai kaedah doktrinal undang-undang dengan mengkaji peruntukan 
undang-undang berkaitan iaitu termasuklah Perjanjian TRIPS sebagai rangka asas 
perundangan di peringkat antarabangsa, akta-akata berkiatan di Nigeria iaitu Patent 
and Design Act, Cap P2, laws of the Federation of Nigeria 2004 dan the National 
Agency for Food and Drug Administration and Control Act, CAP N1 Laws of the 
Federation of Nigeria 2004 serta kes undang-undang yang berkaitan. Kajian ini 
mendapati bahawa kebenaran lesen wajib kepada pihak ketiga di bawah undang-
undang paten mempunyai kesan positif dalam dalam memerangi ubat-ubatan palsu 
sebagai amalan yang merangsang persaingan sihat di kalangan syarikat-syarikat 
farmaseutikal yang seterusnya boleh menurunkan harga ubat-ubatan tulen yang 
dipatenkan dan pada masa yang sama tidak menggalakkan orang ramai daripada 
membeli ubat-ubatan tiruan. Kajian ini mengesyorkan bahawa pihak berkuasa di 
Nigeria harus menggalakkan amalan lesen wajib ke atas ubat-ubatan berpaten bagi 
membantu orang ramai mendapatkan akses kepada ubat-ubatan yang berkualiti serta 
mampu dibeli. 
 
Kata kunci: lessen wajib, ubat-ubatan tiruan, paten, ubat-ubatan berkualiti. 
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ABSTRACT 
The negative implication of the existence of counterfeit drugs to the public, 
government and pharmaceutical companies urge legal interruption to curb the 
problem.  
The objective of this study is to identify how the relevant laws on compulsory 
licensing can be used to address the proliferation of counterfeit drugs in Nigeria. 
 
In answering the question, this study employed doctrinal legal method by examining 
the relevant legal provisions dealing with counterfeit drugs that include TRIPS 
Agreement as the basis of international framework and the Patent and Design Act, Cap 
P2, laws of the Federation of Nigeria 2004 and the National Agency for Food and 
Drug Administration and Control Act, CAP N1 Laws of the Federation of Nigeria 
2004.The content analysis is used in analyzing the data collected in this research. 
 
The study found out that the concept of compulsory licensing practised under the 
patents law has the positive effect in enhancing access to affordable drugs through the 
authorization given 3rd party which subsequently stimulate to a healthy competition 
among pharmaceutical companies.    
The study thus recommended that the authority in Nigeria should encourage the 
practise of compulsory licensing over patented drugs in order to assist the public to 
get access to a good quality and affordable drugs.  
Keyword: compulsory licensing, counterfeit drugs, quality and affordable drugs 
and patenting of drugs. 
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                                                 CHAPTER ONE:  
        OVERVIEW OF THE STUDY 
1.1. INTRODUCTION 
The importance of drugs in the medical parlance cannot be overemphasized as they 
play a prominent role in the diagnosis, treatment and prevention of different types of 
diseases as well as in the restoration of the health of the patients who consumed them.1 
Furthermore, the provision of affordable, accessible and safe drugs constitutes one of 
the determinants used in ascertaining the effectiveness of a health care system.2  
 
 Globally, Article 25 of the United Nation’s Universal Declaration of Human Right 
1948 confers upon every human being with the right to be provided access to medical 
care.3  Regionally, Article 16 of the African Charter on Human and Peoples’ Right 
(Ratification and Enforcement) Act 19904 also confers upon every person with the 
right to have his physical and mental wellbeing protected.   
     
In Nigeria, several statutory provisions imposed a duty on the government to evolve 
policies that are tilted towards the enhancement of the citizen’s health status.  For 
instance section 17(3) (d) of the 1999 Constitution of the Federal Republic of Nigeria 
                                                          
1 Olugbenga Ebenezer Olatunji, “The Politics and Pathology of Drug Service Administration in Third 
World Countries: Lessons of Two Drug Distribution Experiments in Nigeria,”  Research on 
Humanities and Social Sciences 4 no. 8 
(2014):1, http://www.iiste.org/Journals/index.php/RHSS/article/view/12472. ( accessed January7, 
2015). 
2  Ibid. 
3 “The Universal Declaration of Human Right”, http://www.un.org/en/documents/udhr/ (accessed May 
6, 2015). 
4 Chapter A9, Laws of the Federation of Nigeria 1990, http://www.nigeria-
law.org/African%20Charter%20on%20Human%20and%20Peoples%27%20Rights.htm (accessed 
January 7, 2015). 
The contents of 
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